SCHEMBL26599129

SCHEMBL26599129

O=C(CC(F)(F)F)c1cccc(Br)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2R P25116 1/20 0.46
CES2 O00748 1/20 0.36
BCHE P06276 1/20 0.36
CES1 P23141 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
ALDH1A1 P00352 3/20 0.33
LMNA P02545 3/20 0.33
MAOB P27338 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 2/20 0.33
HTT P42858 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
CTSL P07711 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
PRNP P04156 1/20 0.33
GAA P10253 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30606598 1.00 F2R (0.46) F2RCES2BCHECES1SMN1; SMN2
SCHEMBL14833514 0.83 F2R (0.38) F2RCES2BCHECES1SMN1; SMN2
SCHEMBL22051489 0.80 PTPN1 (0.50) CES2BCHECES1SMN1; SMN2ALDH1A1
SCHEMBL16396857 0.80 CES2 (0.39) F2RCES2BCHECES1SMN1; SMN2
SCHEMBL30961290 0.80 PTPN1 (0.50) CES2BCHECES1SMN1; SMN2ALDH1A1
SCHEMBL26599128 0.79 KAT6A (0.41) CES2BCHECES1ALDH1A1
SCHEMBL31174643 0.79 KAT6A (0.41) CES2BCHECES1ALDH1A1
SCHEMBL26622035 0.79 F2R (0.44) F2RCES2BCHECES1SMN1; SMN2
SCHEMBL2782446 0.77 PLA2G2D (0.41) F2RCES2BCHECES1SMN1; SMN2
SCHEMBL15633361 0.76 CES2 (0.36) F2RCES2BCHECES1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339402-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2025-11-06 US disclosed
EP-4511355-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FundaMental Pharma GmbH (DE) 2025-02-26 EP disclosed
WO-2024223617-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2024-10-31 WO disclosed
WO-2023203254-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2023-10-26 WO disclosed
WO-2023203254-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339402-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY TRPM4, GRM4, GRIN1 F2R 1356/4885CES2 3965/4885BCHE 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.